ReGenica May Offer Hope for Hair Loss Sufferers

A new formula hair growth formula called ReGenica is scheduled to present preliminary mid-trial results of the first human clinical evaluation. The purpose of this double-blind, randomized study is to evaluate safety in the clinical application of the ReGenica product for hair regrowth. Trial researchers are also examining product efficacy as a secondary objective, specifically looking at the same end-points they have seen in the animal model - new hair growth, and the thickness of new and existing hair.


Dr. Craig Ziering, principal investigator of the study and founder of Ziering Medical said, "ReGenica's clinical trial was designed to assess the safety of the product over a five month period. In addition to seeing no adverse reactions, we were delighted to see more hair, thicker hair shafts, and what appears to be the growth of completely new hair follicles in the areas that received the ReGenica treatment."

ReGenica is a proprietary liquid formula created by the culturing of newborn fibroblasts in an embryonic-like environment, and then harvesting the naturally secreted embryonic WNT proteins, growth factors, and other synergistic bioproducts that are produced. It is the first naturally stabilized and bioactive formulation of WNT proteins and natural cofactors, which are thought to act in the formation of new hair follicles.

"Wnt signaling has been shown to be responsible for initiating epidermal stem cells to form new hair follicles in mice, and is also important in maintaining the hair inducing activity from existing follicles," said Frank Zeigler, General Manager at parent company, Histogen. "We are excited to be the first group to show these effects in a clinical setting using human WNT proteins."

Histogen began this outside-U.S. study of ReGenica for hair regrowth in November, with the goal of more rapidly obtaining human safety data which will allow the Company to progress with product development. The trial is currently ongoing, and Histogen expects to release full results from this first clinical study in the first half of 2009.


Disclaimer

Featured Specialities:

Featured Doctors: